CordenPharma Invests €900M in Peptide Manufacturing Expansion to Meet Rising Demand for GLP-1 Medications

1. Investment Amount: CordenPharma is investing approximately €900 million over the next three years to expand its peptide manufacturing capabilities in the US and Europe.
2. GLP-1 Demand: The investment is driven by the growing demand for GLP-1 medications, particularly for diabetes and obesity treatments.
3. US Expansion: The Colorado, US site will see additional large-scale peptide manufacturing capacity to meet the increasing demand for GLP-1 peptides, with multiple long-term contracts totaling €3 billion.
4. European Expansion: A new greenfield site will be constructed in Europe for small to large-scale peptide development and manufacturing, integrated within CordenPharma's global facility network.
5. Sales Target: The expansion aims to help CordenPharma reach €1 billion in sales for its Peptide Platform and €1.8 billion in total group revenue by 2028.
6. Quality Standards: The expansions will meet the pharmaceutical industry's most stringent quality and technical standards, including Biologics License Applications (BLA) requirements.